373 related articles for article (PubMed ID: 23134728)
1. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
Parikh C; Janakiraman V; Wu WI; Foo CK; Kljavin NM; Chaudhuri S; Stawiski E; Lee B; Lin J; Li H; Lorenzo MN; Yuan W; Guillory J; Jackson M; Rondon J; Franke Y; Bowman KK; Sagolla M; Stinson J; Wu TD; Wu J; Stokoe D; Stern HM; Brandhuber BJ; Lin K; Skelton NJ; Seshagiri S
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19368-73. PubMed ID: 23134728
[TBL] [Abstract][Full Text] [Related]
2. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
[TBL] [Abstract][Full Text] [Related]
3. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
[TBL] [Abstract][Full Text] [Related]
4. ATP-competitive and allosteric inhibitors induce differential conformational changes at the autoinhibitory interface of Akt1.
Shaw AL; Parson MAH; Truebestein L; Jenkins ML; Leonard TA; Burke JE
Structure; 2023 Mar; 31(3):343-354.e3. PubMed ID: 36758543
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
Landgraf KE; Pilling C; Falke JJ
Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
[TBL] [Abstract][Full Text] [Related]
6. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis.
Yin S; Liu L; Brobbey C; Palanisamy V; Ball LE; Olsen SK; Ostrowski MC; Gan W
Nat Commun; 2021 Jun; 12(1):3444. PubMed ID: 34103528
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.
Dannemann N; Hart JR; Ueno L; Vogt PK
Int J Cancer; 2010 Jul; 127(1):239-44. PubMed ID: 19876913
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.
Wu WI; Voegtli WC; Sturgis HL; Dizon FP; Vigers GP; Brandhuber BJ
PLoS One; 2010 Sep; 5(9):e12913. PubMed ID: 20886116
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Wan PT; Garnett MJ; Roe SM; Lee S; Niculescu-Duvaz D; Good VM; Jones CM; Marshall CJ; Springer CJ; Barford D; Marais R;
Cell; 2004 Mar; 116(6):855-67. PubMed ID: 15035987
[TBL] [Abstract][Full Text] [Related]
10. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
Guo JP; Coppola D; Cheng JQ
J Biol Chem; 2011 Oct; 286(43):37389-98. PubMed ID: 21908616
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.
Yi KH; Axtmayer J; Gustin JP; Rajpurohit A; Lauring J
Oncotarget; 2013 Jan; 4(1):29-34. PubMed ID: 23237847
[TBL] [Abstract][Full Text] [Related]
12. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
13. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.
Kim D; Sun M; He L; Zhou QH; Chen J; Sun XM; Bepler G; Sebti SM; Cheng JQ
J Biol Chem; 2010 Mar; 285(11):8383-94. PubMed ID: 20068047
[TBL] [Abstract][Full Text] [Related]
14. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
15. PH domain-mediated autoinhibition and oncogenic activation of Akt.
Bae H; Viennet T; Park E; Chu N; Salguero A; Eck MJ; Arthanari H; Cole PA
Elife; 2022 Aug; 11():. PubMed ID: 35968932
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.
Chen G; Park D; Magis AT; Behera M; Ramalingam SS; Owonikoko TK; Sica GL; Ye K; Zhang C; Chen Z; Curran WJ; Deng X
Cancer Res; 2019 Dec; 79(24):6126-6138. PubMed ID: 31662324
[TBL] [Abstract][Full Text] [Related]
17. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.
Meuillet EJ; Mahadevan D; Vankayalapati H; Berggren M; Williams R; Coon A; Kozikowski AP; Powis G
Mol Cancer Ther; 2003 Apr; 2(4):389-99. PubMed ID: 12700283
[TBL] [Abstract][Full Text] [Related]
18. The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3,4,5)P(3).
Pilling C; Landgraf KE; Falke JJ
Biochemistry; 2011 Nov; 50(45):9845-56. PubMed ID: 21932773
[TBL] [Abstract][Full Text] [Related]
19. Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain.
Kumar A; Purohit R
PLoS One; 2013; 8(5):e64364. PubMed ID: 23741320
[TBL] [Abstract][Full Text] [Related]
20. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
